Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Tue, 14.06.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, South San Francisco, United States, June 14, 2022
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed b [ … ]
Mon, 13.06.2022
MorphoSys AG
Media Release
New York, New York, U.S.; Boston, Massachusetts, U.S.; and Wilmington, Delaware, U.S., June 13, 2022
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned sub [ … ]
Fri, 10.06.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, June 10, 2022
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib- [ … ]
Wed, 18.05.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 18, 2022
MorphoSys AG Reports Outcome of Annual General Meeting 2022
All Proposed Resolutions Approved
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General [ … ]
Thu, 12.05.2022
MorphoSys AG
Media Release
BOSTON, Mass., USA, May 12, 2022
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
Efficacy and safety data from the ongoing Phase 2 MANIFEST study of pelabresib in myelofibrosis will be featur [ … ]
Wed, 04.05.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 4, 2022
MorphoSys AG Reports First Quarter 2022 Financial Results
- Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth
- NCCN® updated the designation of Monjuvi to preferred regimen in its Clinical Practice Guidelines in Oncolog [ … ]
Thu, 28.04.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, April 28, 2022
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT).
MorphoSys' Management team will host a conf [ … ]
Tue, 22.03.2022
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland addressing an urgent unmet medical need
- In [ … ]
Wed, 16.03.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 16, 2022
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Monjuvi(R) U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year 2021
- Pipeline advances: enrollment [ … ]
Tue, 15.03.2022
MorphoSys AG
Media Release
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
BOSTON, Mass., USA - March 15, 2022 - MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), announced today that the [ … ]